Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Kura Oncology (DE:KUR)
FRANKFURT:KUR
Kura Oncology (KUR) Stock Price & Analysis
0 Followers
KUR Stock Chart & Stats
Day’s Range€0 - €0
52-Week Range€7.05 - €21.40
Previous Close€18.64
Volume0.00
Average Volume (3M)221.00
Market Cap
€1.43B
Enterprise Value€1.03B
Total Cash (Recent Filing)$452.59M
Total Debt (Recent Filing)$17.42M
Price to Earnings (P/E)N/A
Beta0.07
Next Earnings
May 07, 2024EPS Estimate
-€0.5Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding76,136,963
10 Day Avg. Volume0
30 Day Avg. Volume221
Standard DeviationN/A
R-SquaredN/A
AlphaN/A
Financial Highlights & Ratios
Price to Book (P/B)3.90
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-11.30
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit10.00T>
Enterprise Value/Ebitda-7.34
Forecast
1Y Price Target
€28.69Price Target Upside54.29% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering12
Kura Oncology News
Options Prices
Currently, No data available
---
Ownership Overview
0.00% Insiders
0.00% Mutual Funds
64.49% Other Institutional Investors
35.51% Public Companies and
Individual Investors
KUR FAQ
What was Kura Oncology’s price range in the past 12 months?
Kura Oncology lowest stock price was €7.05 and its highest was €21.40 in the past 12 months.
What is Kura Oncology’s market cap?
Currently, no data Available
When is Kura Oncology’s upcoming earnings report date?
Kura Oncology’s upcoming earnings report date is May 07, 2024 which is in 8 days.
How were Kura Oncology’s earnings last quarter?
Kura Oncology released its earnings results on Feb 27, 2024. The company reported -€0.508 earnings per share for the quarter, beating the consensus estimate of -€0.508 by <€0.001.
Is Kura Oncology overvalued?
According to Wall Street analysts Kura Oncology’s price is currently Undervalued.
Does Kura Oncology pay dividends?
Kura Oncology does not currently pay dividends.
What is Kura Oncology’s EPS estimate?
Kura Oncology’s EPS estimate is -€0.5.
How many shares outstanding does Kura Oncology have?
Currently, no data Available
What happened to Kura Oncology’s price movement after its last earnings report?
Kura Oncology reported an EPS of -€0.508 in its last earnings report, beating expectations of -€0.508. Following the earnings report the stock price went up 4.737%.
Which hedge fund is a major shareholder of Kura Oncology?
Among the largest hedge funds holding Kura Oncology’s share is Deerfield Management Company, LP. It holds Kura Oncology’s shares valued at 76M.
---
Kura Oncology Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
€28.69 (54.29% Upside)
€28.69 (54.29% Upside)
Blogger Sentiment
Bullish
DE:KUR Sentiment 100%
Sector Average 71%
Sector Average 71%
Insider Transactions
Sold Shares
Worth $205.2K over
the Last 3 Months
the Last 3 Months
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
70.51%
12-Months-Change
Fundamentals
Return on Equity
-37.34%
Trailing 12-Months
Asset Growth
-1.62%
Trailing 12-Months
Company Description
Kura Oncology
Kura Oncology, Inc. operates as a clinical-stage biopharmaceutical company which engages in the research and development of medicines for the treatment of cancer. Its pipeline includes Tipifarnib which is a Farnesyl transferase inhibitor for HRAS Mutant Solid Tumors, Chronic Myelomonocytic Leukemia; KO-947 which is an ERK inhibitor for MAPK Pathway Tumors; and KO-539 which is a Menin MLL inhibitor for acute leukemias. The company was founded by Troy E. Wilson, Yi Liu, Pingda Ren and Antonio Gualberto on August 22, 2014 and is headquartered in La Jolla, CA.
---
KUR Earnings Call
Q4 2024
0:00 / 0:00
---
KUR Stock 12 Months Forecast
Average Price Target
€28.69
▲(54.29% Upside)
Technical Analysis
Kura Oncology
―
Karyopharm Therapeutics
―
Kodiak Sciences
―
Krystal Biotech
―
Prothena
―
Best Analysts Covering KUR
1 Year
1 Year Success Rate
10/16 ratings generated profit
1 Year Average Return
+46.25%
reiterated a buy rating 2 months ago
Copying Joseph Pantginis's trades and holding each position for 1 Year would result in 62.50% of your transactions generating a profit, with an average return of +46.25% per trade.
---